Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Acetyl-L-Glutamate is an endogenous amino acid derivative that functions as a crucial metabolic intermediate, particularly in bacterial arginine biosynthesis. It is also recognized as an essential allosteric activator of carbamoyl phosphate synthetase 1 (CPS1), the initial and rate-limiting enzyme in the urea cycle, which is critical for the detoxification of ammonia. Deficiency in N-Acetyl-L-Glutamate is associated with N-acetylglutamate synthase deficiency (NAGSD), a urea cycle disorder. Its levels are observed to be altered in various physiological and pathological states, including ulcerative colitis, Parkinson's disease, diabetic retinopathy, hyperuricemia, and in response to immune stress or specific dietary interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-Acetyl-L-Glutamate.